This independent CME/CE activity is supported by an educational grant from EMD Serono, Inc..




Chair
faculty image
Thomas P. Leist, MD, PhD
  • Chief, Division of Clinical Neuroimmunology
  • Thomas Jefferson University
  • Philadelphia, Pennsylvania

  • Date:
    Saturday, February 03, 2018
    Time:
    3:15 PM 
    Registration/Refreshments 

     
    3:45–5:00 PM 
    Scientific Session 
    Location:
    Hilton San Diego Bayfront
    1 Park Blvd.
    San Diego, California

    Registration for the live symposium has now ended.

    If you would like to attend this live event, please arrive at the Hilton San Diego Bayfront Hotel, Indigo Ballroom, 1 Park Blvd, San Diego, by 3:15pm for onsite registration.


    Multiple sclerosis (MS) is a chronic immune-mediated inflammatory and neurodegenerative disorder. Advances in our understanding of MS immunopathology have led to the identification of new therapeutic targets and the development of new therapies, with 16 disease-modifying therapies currently available and several additional agents in late-stage clinical development. Most of these treatments involve the chronic use of a maintenance therapy to induce remission. However, pulsed immune reconstitution therapy (PIRT) is a treatment approach that works by either transiently or permanently resetting the immune system, with the potential to induce long-term remission or even cure. This program will provide expert insight into the role of immune dysfunction in MS, the current treatment landscape for MS patients, and the possibility of using PIRT treatments to induce drug-free remission in MS patients. Join Dr. Thomas Leist, our program chair, and our distinguished faculty Drs. Kottil Rammohan and Gavin Giovannoni for a 75-minute satellite symposium on Saturday, February 3 at 3:45 pm.

    This program is not part of the official ACTRIMS Forum 2018.
    AGENDA
    3:45 PM
    Introduction
    Thomas P. Leist, MD, PhD
    3:50 PM
    Immune Dysfunction and MS
    Thomas P. Leist, MD, PhD
    4:00 PM
    Insights on the Current Treatment Options for MS and Continuous Immunosuppression
    Kottil W. Rammohan, MD
    4:25 PM
    Strategies for Optimizing Outcomes for MS Patients: Is Drug-free Remission Possible?
    Gavin Giovannoni, MBBCh, PhD, FCP
    4:50 PM
    Q&A and Final Remarks
    Thomas P. Leist, MD, PhD
    CME/CE Information

    Estimated time for completion of this activity:

    CME: 1.25 hours
    CNE:  1.25 hours
    CPE:  1.25 hours

    Target Audience

    This CME/CE activity is designed for neurologists, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other clinicians involved in the management and care of patients impacted by multiple sclerosis.

    Activity Goal

    The goal of this program is to provide clinicians with new insights on immune dysfunction associated with multiple sclerosis, a better understanding of immune resetting therapies, and personalized treatment strategies that have the potential to improve patient outcomes.

    Learning Objective(s)

    • Analyze immune dysfunction in multiple sclerosis (MS) and the potential for resetting the immune system to allow for drug-free remission.
    • Evaluate the role of continuous drug sequencing/maintenance therapy vs pulsed immune reconstitution therapy on the immune system in MS.
    • Formulate risk/benefit strategies to optimize treatment selection based on an understanding of the effect of current therapies on the immune system.


    CME Information: Physicians


    Statement of Accreditation

    Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    Projects In Knowledge® designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CE Information: Nurses

    Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Upon completion of this course, participants will be awarded 1.25 nursing contact hour(s).

    DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, or PIK endorsement of any commercial product or service.

    CE Information: Pharmacists

    Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

    This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This satellite symposium is worth up to 1.25 contact hour(s) (0.125 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-18-001-L01-P.

    Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

    CME/CE Instructions


    To obtain credit for the live meeting:

    1. Sign in at the registration desk.
    2. Attend the live satellite symposium.
    3. Complete the evaluation form.
    4. Submit it to the event representative as you exit.
    5. Your certificate will be emailed to you within 4 weeks of the activity date.

    There is no fee for this activity.

    CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

    Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

    For more information on the contract, click here.

    Disclosure Information

    The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.

    Thomas P. Leist, MD, PhD has received honoraria, consulting fees, and fees for non-CME services from Biogen, Genentech, Novartis AG, Sanofi-Genzyme, and Teva Pharmaceutical Industries, Ltd; and has contracted research from Alkermes and Chugai Pharmaceutical Co, Ltd.

    Gavin Giovannoni, MBBCh, PhD, FCP has received honoraria from AbbVie, Almirall, Atara Biotherapeutics, Biogen, EMD Serono, Inc, Hoffman-La Roche Ltd, Novartis AG, Sanofi Genzyme, and Teva Pharmaceutical Industries, Ltd; consulting fees from AbbVie, Atara Biotherapeutics, Biogen, EMD Serono, Inc, Genentech, GlaxoSmithKline, Hoffman-La Roche Ltd, Novartis AG, Sanofi Genzyme, and Teva Pharmaceutical Industries, Ltd; and fees for non-CME services from Biogen, EMD Serono, Inc, Hoffman-La Roche Ltd, and Novartis AG.

    Kottil W. Rammohan, MD has received honoraria from Biogen, EMD Serono, Genentech, Novartis AG, and Sanofi Genzyme; consulting fees from Biogen, EMD Serono, Genentech, and Sanofi Genzyme; and has contracted research from Genentech, Novartis, and the United States Department of Defense.

    Peer Reviewer has disclosed no relevant relationships.

    Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.

    Kirstin Bass, MD, PhD (medical writer) has disclosed no relevant relationships.

    Projects In Knowledge's staff members have no relevant relationships to disclose.

    Planning Committee
    Gavin Giovannoni, MBBCh, PhD, FCP has received honoraria from AbbVie, Almirall, Atara Biotherapeutics, Biogen, EMD Serono, Inc, Hoffman-La Roche Ltd, Novartis AG, Sanofi Genzyme, and Teva Pharmaceutical Industries, Ltd; consulting fees from AbbVie, Atara Biotherapeutics, Biogen, EMD Serono, Inc, Genentech, GlaxoSmithKline, Hoffman-La Roche Ltd, Novartis AG, Sanofi Genzyme, and Teva Pharmaceutical Industries, Ltd; and fees for non-CME services from Biogen, EMD Serono, Inc, Hoffman-La Roche Ltd, and Novartis AG.
    Thomas P. Leist, MD, PhD has received honoraria, consulting fees, and fees for non-CME services from Biogen, Genentech, Novartis AG, Sanofi-Genzyme, and Teva Pharmaceutical Industries, Ltd; and has contracted research from Alkermes and Chugai Pharmaceutical Co, Ltd.
    Kottil W. Rammohan, MD has received honoraria from Biogen, EMD Serono, Genentech, Novartis AG, and Sanofi Genzyme; consulting fees from Biogen, EMD Serono, Genentech, and Sanofi Genzyme; and has contracted research from Genentech, Novartis, and the United States Department of Defense.

    Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

    The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

    This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

    This independent CME/CE activity is supported by an educational grant from EMD Serono, Inc..

    Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.


    2338 1